Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.80 per share for the third quarter of 2025, surpassing the Zacks Consensus Estimate of $4.55. Earnings rose around 10% year over year.

Vertex Pharmaceuticals (VRTX) is gaining attention as new clinical data for its kidney disease therapy, povetacicept, shows encouraging results. The company’s portfolio is also benefiting from steady ...

I’m upgrading Vertex to a "Neutral" rating after its sharp stock decline corrected prior valuation concerns, but risks remain substantial. Vertex balances mid-teens revenue growth with high-teens ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including federal ...

Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis (CF) ...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. By Gina Kolata The Food and Drug Administration approved a new medication Thursday to treat pain ...